Category Archives: Hassan Q1 Conference Call Schering Vytorin Zetia Organo

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .

Advertisements

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .

CEO Fred Hassan’s Call Transcript Now Online. See the Dodge.

Here it is, courtesy of seekingalpha:

. . . .Jamie Rubin – Morgan Stanley:

Wait, wait. And what about my other question… my first question, on Merck’s more specific VYTORIN, ZETIA guidance?

Fred Hassan – Chairman and Chief Executive Officer:

Bob?

Robert J. Bertolini – Executive Vice President and Chief Financial Officer:

We will [not?] provide numeric guidance Jamie.

Fred Hassan – Chairman and Chief Executive Officer:

Yes, Jamie, I think you did hear the market share delta between March and December and then you also heard that there’s another drop that’s occurred after the ACC. I think what I said is that there is no model that we can relate to that would… that can give us any prediction. The previous models have been related to side effect issues and we have a very strange situation here where there’s a U.S. media driven situation which is quite different from outside the U.S. There are no months to be looking at here. But the reality is that science is strong and we’re going to work hard to recapture a lot of the market share that we’ve lost. It’s hard to predict when that recapture will start to occur. Because at this time there is still a lot of confusion out there only in the U.S. market. . . .

[Emphasis supplied.]

This will not go down well, at the SEC, when compared to his Form 8-K, filed only yesterday.

It is always the little stuff. . . .